Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neogenix Oncology

Request full access

Neogenix Oncology develops novel therapeutic and diagnostic products for the treatment of cancer patients

Town of North Hempstead, United StatesFounded 2003Biotech & Life Sciences

About Neogenix Oncology

Neogenix Oncology, Inc. was a clinical-stage biotechnology company founded in 2003 by Dr. Myron Arlen. The firm was established to build upon the pioneering immunotherapy work of Dr. Arlen and his collaborator, Dr. Ariel Hollinshead, who had isolated various tumor-associated antigens (TAAs) in the 1970s and 1980s. Dr. Arlen, a surgical oncologist at Memorial Sloan-Kettering and North Shore University Hospital, recognized the untapped potential of Dr. Hollinshead's library of cancer vaccines, which had shown promise in early clinical trials but could not be fully analyzed with the technology of that era.

The company focused on developing therapeutic and diagnostic antibodies for the treatment of various cancers, including pancreatic, colorectal, lung, and prostate cancer. Its business model centered on advancing a pipeline of monoclonal antibodies (mAbs) and their corresponding companion diagnostics. In 2004, Neogenix acquired sole ownership of the Hollinshead library of vaccines, antibodies, and antigens. The company's lead candidate, NEO-101 (Ensituximab), was a monoclonal antibody that entered Phase IIa trials for colorectal and pancreatic cancer. Other candidates, NEO-201 and NEO-301, were in the preclinical stage. To support its clinical programs, Neogenix formed partnerships, such as an agreement with Cambridge Biomedical, Inc. in 2011 to develop diagnostic serum ELISA assays.

Over its operational history, Neogenix Oncology raised a total of $15.8 million in funding over two rounds. Despite its efforts, the company faced financial challenges. In June 2012, it entered into a non-binding letter of intent with Precision Biologics, Inc., a corporation funded by several Neogenix shareholders, for the acquisition of its assets through a Chapter 11 bankruptcy proceeding. The following month, an asset purchase agreement was signed, and in September 2012, Precision Biologics officially acquired Neogenix's library of vaccines, antibodies, antigens, and other assets. Following the acquisition, Neogenix Oncology was classified as an acqui-hired, deadpooled company.

Source: Dealroom company data

Neogenix Oncology in the Town of North Hempstead ecosystem

Live from Dealroom

The Neogenix Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Town of North Hempstead HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neogenix Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neogenix Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.